Brughera Marco Maria 4

What Happened

• Marco Brughera, a director of Fennec Pharmaceuticals (FENC), was granted a non‑qualified stock option to purchase 20,000 common shares. The option strike price is $8.70 per share, representing a reported aggregate value of $174,000. This is an award (compensation), not a sale or open‑market purchase.

Key Details

• Transaction date: June 10, 2026; Filing date: June 10, 2026 (timely).
• Instrument: Non‑qualified stock option (derivative); 20,000 shares; exercise price $8.70; reported value $174,000.
• Vesting: The option is 100% vested on the date of grant (per footnote).
• Shares owned after transaction: Not disclosed in the filing excerpt.
• Footnotes: Grant made pursuant to the issuer's Equity Incentive Plan; fully vested at grant.
• Filing timeliness: Reported on the same date as the transaction (no late filing indicated).

Context

• This report documents an option grant (award). Because the option is fully vested on grant, Brughera could exercise immediately, but exercising would be a separate transaction and would be reported differently (e.g., exercise and/or stock sale would generate additional Form 4 entries). Awards are routine forms of executive/director compensation and do not by themselves indicate a buy or sell opinion.